Ikena Oncology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 43
- Market Cap
- $83.7M
- Website
- http://www.ikenaoncology.com
- Introduction
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
HUTCHMED Reports 65% Growth in Oncology Products Revenue, Achieves Profitability in 2024
• HUTCHMED achieved net income of $37.7 million in 2024, reaching profitability ahead of schedule with strong oncology products revenue growth of 65% to $271.5 million.
• FRUZAQLA® (fruquintinib) demonstrated impressive global commercial performance with ex-China in-market sales of $290.6 million in its first full year, triggering sales milestone payments from Takeda.
• The company is advancing its innovative ATTC (Antibody-Targeted Therapy Conjugate) platform and progressing multiple pipeline candidates, including positive data for savolitinib in NSCLC and sovleplenib for ITP.
DelveInsight Report: Over 50 Pipeline Drugs in Development for Urothelial Carcinoma Treatment
• DelveInsight's latest pipeline analysis reveals 40+ pharmaceutical companies actively developing 50+ therapeutic candidates for urothelial carcinoma treatment, indicating robust research activity in this space.
• Major pharmaceutical companies including AstraZeneca, Seagen, and Janssen are advancing promising therapies, with notable candidates like disitamab vedotin and cetrelimab in late-stage development.
• Recent clinical trials include Seagen's Phase 2 study of disitamab vedotin with pembrolizumab, and Roche's Phase 1b/II umbrella study investigating multiple combination therapies for advanced urothelial carcinoma.
Pharmaceutical Industry Faces Widespread Layoffs Amid Patent Cliffs and Economic Uncertainty
• Major pharmaceutical companies including Pfizer, Novartis, and Takeda have implemented significant workforce reductions over the past year due to patent cliffs and economic pressures.
• Unlike previous trends, current layoffs are heavily impacting R&D departments, marking a shift from traditional commercial-focused cuts and reflecting the industry's evolving outsourcing landscape.
• Contract Research Organizations (CROs) are benefiting from the industry shift, absorbing displaced talent and gaining additional business as pharmaceutical companies restructure their operations.
© Copyright 2025. All Rights Reserved by MedPath